OverviewSuggest Edit

Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
TypePublic
Founded2006
HQEmeryville, US
Websitezogenix.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2018)90(+33%)
Job Openings27
Revenue (FY, 2017)$9.8 M(-65%)
Share Price (May 2019)$37.4

Zogenix Office Locations

Zogenix has offices in Emeryville and Windsor and Maidenhead
Emeryville, US (HQ)
5858 Horton St #455
Windsor and Maidenhead, GB
Siena Court The Broadway
Show all (2)

Zogenix Financials and Metrics

Zogenix Revenue

Zogenix's revenue was reported to be $9.82 m in FY, 2017
USD

Net income (Q1, 2019)

(35.2m)

EBIT (Q1, 2019)

(38.3m)

Market capitalization (17-May-2019)

1.6b

Closing stock price (17-May-2019)

37.4

Cash (31-Mar-2019)

58.3m
Zogenix's current market capitalization is $1.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

33.0m40.5m27.2m28.9m9.8m

Revenue growth, %

23%(33%)6%

Cost of goods sold

21.2m15.8m10.7m

Gross profit

11.8m24.7m28.9m(908.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

7.2m7.7m9.2m8.8m4.6m7.4m9.1m9.2m2.1m6.6m2.7m7.1m

Cost of goods sold

5.4m3.4m2.4m706.0k7.8m2.1m6.4m2.5m8.2m

Gross profit

1.8m4.3m6.8m8.1m1.4m27.0k179.0k209.0k(1.1m)

Gross profit Margin, %

25%56%74%92%15%1%3%8%(16%)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

72.0m42.2m155.3m91.6m293.5m68.5m

Accounts Receivable

6.7m1.4m1.4m

Inventories

9.9m13.4m12.0m12.0m

Current Assets

92.9m78.0m184.6m119.9m304.7m532.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

17.4m50.7m81.2m50.5m21.3m77.4m162.7m132.2m127.8m109.9m80.1m65.8m64.7m272.0m272.1m163.0m58.3m

Accounts Receivable

6.2m11.7m5.9m5.9m1.6m6.0m3.9m4.9m2.1m6.5m15.5m

Inventories

12.1m14.9m15.7m19.3m13.1m12.6m10.3m9.5m11.9m9.4m9.1m2.2m

Current Assets

37.4m81.0m116.5m90.6m55.2m125.3m200.6m163.1m149.5m135.3m98.8m78.8m70.7m281.3m285.1m547.3m510.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(80.9m)8.6m26.1m(69.7m)(126.8m)(123.9m)

Depreciation and Amortization

1.8m1.6m1.6m1.4m425.0k155.0k

Inventories

3.0m(9.2m)1.4m(743.0k)2.6m

Accounts Payable

6.1m5.6m(14.2m)(14.2m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(45.2m)49.6m35.0m(10.4m)(29.2m)(46.2m)(21.3m)(44.3m)(87.1m)(30.2m)(59.2m)(101.5m)(35.2m)

Depreciation and Amortization

1.4m406.0k820.0k1.2m393.0k814.0k1.2m378.0k694.0k966.0k213.0k366.0k408.0k23.0k50.0k76.0k191.0k

Inventories

542.0k3.0m2.6m186.0k2.6m(2.1m)2.6m2.6m

Accounts Payable

205.0k6.9m10.7m2.4m947.0k(9.9m)(11.6m)(4.3m)(3.9m)(4.3m)
USDY, 2019

Financial Leverage

1.3 x
Show all financial metrics

Zogenix Online and Social Media Presence

Embed Graph

Zogenix News and Updates

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm

NEW YORK, April 22, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...

Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, Duluth Holdings, Inc., Establishment Labs Holdings Inc., Flex Ltd., Global Brass and Copper Holdings, Inc., Indivior PLC, Papa Murphy's Holdings, Inc., and Zogenix, Inc.

NEW YORK, April 17, 2019 /PRNewswire/ -- Anadarko Petroleum Corporation (APC) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale of Anadarko to Chevron Corporation. If you are an Anadarko investor, and would like...

ZGNX CLASS ACTION ALERT: Hagens Berman Alerts Zogenix (ZGNX) Investors to Securities Class Action, Encourages Investors to Contact the Firm

According to the complaint, Defendants misled investors about Zogenix’s much-anticipated New Drug Application (“NDA”) for FINTEPLA®.  More specifically, according to the complaint, the NDA (1) contained inadequate non-clinical data and an incorrect version of a clinical dataset, and (2) consequently…

Hagens Berman Alerts Zogenix (ZGNX) Investors of the Firm's Investigation of Possible Securities Law Violations, Encourages Investors to Contact the Firm

SAN FRANCISCO, April 15, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Zogenix, Inc. (NASDAQ: ZGNX) to the firm's investigation of possible Federal securities law violations. If you purchased or otherwise acquired Zogenix securities between January 1, 2019 and...

Former California Deputy Attorney General and Special Counsel with Johnson Fistel Launches Investigation into Zogenix, Inc. (ZGNX)

SAN DIEGO, April 13, 2019 /PRNewswire/ -- Johnson Fistel, LLP with the assistance of former California Deputy Attorney General and Special Counsel, Tiffany Johnson, Esq., is investigating potential claims against Zogenix, Inc. ("Zogenix") (NASDAQ: ZGNX) for violations of federal...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zogenix, Inc. - ZGNX

NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Show more

Zogenix Blogs

Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application

Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application Content Import Mon, 04/08/2019 - 16:04 Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application 04.08.19…

Zogenix to Present at Two Investor Conferences in April

Zogenix to Present at Two Investor Conferences in April Content Import Mon, 03/25/2019 - 08:04 Zogenix to Present at Two Investor Conferences in April 03.25.19 This release is a backfill from a News Wire General EMERYVILLE, Calif., Ma…

Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan

EMERYVILLE, Calif. , March 19, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into an exclusive distribution agreement with Nippon Shinyaku, Co., Ltd.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results Content Import Thu, 02/28/2019 - 16:07 Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results 02.28.19 This release is …

Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28

EMERYVILLE, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2018 , after the market close,

Zogenix to Present at the 8th Annual SVB Leerink Global Healthcare Conference

EMERYVILLE, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr , President and CEO, will provide a corporate update at the 8 th Annual SVB Leerink Global Healthcare
Show more

Zogenix Frequently Asked Questions

  • When was Zogenix founded?

    Zogenix was founded in 2006.

  • How many employees does Zogenix have?

    Zogenix has 90 employees.

  • Who are Zogenix competitors?

    Competitors of Zogenix include Intarcia Therapeutics, Recro Pharma and BTG.

  • Where is Zogenix headquarters?

    Zogenix headquarters is located at 5858 Horton St #455, Emeryville.

  • Where are Zogenix offices?

    Zogenix has offices in Emeryville and Windsor and Maidenhead.

  • How many offices does Zogenix have?

    Zogenix has 2 offices.